Medicare Enrolled
Dr. Madiha Iqbal, MBBS
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Iqbal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iqbal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iqbal
Dr. Madiha Iqbal is a hematology & oncology specialist in Jacksonville, FL, with 11 years of NPI registration. Based on federal Medicare data, Dr. Iqbal performed 56,204 Medicare services across 2,151 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iqbal received a total of $12,910 from 21 pharmaceutical and/or device companies across 61 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iqbal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 14% volume in FL
$12,910 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 132180 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗56,204
Medicare services
Top 14% in FL for hematology & oncology
2,151
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,109 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 8,000 | $38 | $180 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,750 | $0 | $1 |
| Nivolumab injection (Opdivo) | 6,540 | $24 | $114 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
5,610 | $0 | $2 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
4,860 | $38 | $189 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
4,595 | $2 | $11 |
| Denosumab injection (Prolia/Xgeva) | 2,760 | $18 | $88 |
| Paclitaxel chemotherapy injection | 2,532 | $0 | $2 |
| Paclitaxel protein-bound particle injection An injection of paclitaxel formulated as protein-bound particles. This code specifies the administration of the medication measured in milligrams. |
2,300 | $10 | $51 |
| Injection, durvalumab, 10 mg | 2,172 | $62 | $296 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,496 | $0 | $4 |
| Anti-nausea injection (ondansetron/Zofran) | 1,344 | $0 | $5 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
1,290 | $36 | $137 |
| Bevacizumab-bvzr biosimilar injection, 10 mg An injection of bevacizumab-bvzr, a biosimilar medication, administered in a 10 mg dose. |
1,140 | $23 | $184 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
560 | $3 | $9 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
354 | $12 | $216 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
338 | $41 | $175 |
| Injection, atropine sulfate, 0.01 mg | 335 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 310 | $1 | $9 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
247 | $97 | $869 |
| Injection, leucovorin calcium, per 50 mg | 220 | $3 | $20 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
217 | $2 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 210 | $3 | $34 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
176 | $64 | $296 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
176 | $2 | $31 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
149 | $18 | $135 |
| Injection, potassium chloride, per 2 meq | 140 | $0 | $22 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 135 | $131 | $500 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
113 | $11 | $102 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
112 | $1 | $19 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
97 | $22 | $233 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
94 | $10 | $114 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
81 | $2 | $82 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
71 | $50 | $446 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
69 | $7 | $55 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
67 | $26 | $200 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
63 | $48 | $426 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
61 | $22 | $212 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
58 | $55 | $352 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
57 | $102 | $450 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
56 | $16 | $154 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
42 | $1 | $37 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
33 | $1 | $78 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
32 | $15 | $143 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
27 | $133 | $993 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
23 | $25 | $345 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
20 | $27 | $600 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
19 | $68 | $604 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
14 | $43 | $370 |
| New patient office visit, complex (60-74 min) | 14 | $177 | $891 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
14 | $65 | $348 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $92 | $707 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.5% high complexity
84.7% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,910
Total received (2018-2024)
Avg $2,152/year across 6 years
Top 34% in FL for hematology & oncology
21
Companies
61
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,792 (75.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,851 (22.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$267 (2.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$10,392
2023
$140
2022
$199
2020
$221
2019
$1,304
2018
$655
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SANOFI-AVENTIS U.S. LLC
$9,792
Kite Pharma, Inc.
$735
Amgen Inc.
$426
Celgene Corporation
$284
Genentech USA, Inc.
$279
Alexion Pharmaceuticals, Inc.
$259
Lilly USA, LLC
$213
Seattle Genetics, Inc.
$168
E.R. Squibb & Sons, L.L.C.
$114
Novartis Pharmaceuticals Corporation
$104
Rigel Pharmaceuticals, Inc.
$100
Seagen Inc.
$99
Jazz Pharmaceuticals Inc.
$97
Eli Lilly and Company
$69
Genmab U.S., Inc.
$48
Daiichi Sankyo Inc.
$27
AbbVie Inc.
$27
Kyowa Kirin, Inc.
$23
Janssen Scientific Affairs, LLC
$20
EMD Serono, Inc.
$13
PFIZER INC.
$13
Top 3 companies account for 84.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · Abraxane · Bavencio · CYRAMZA · DARZALEX · Herceptin · INJECTAFER · INREBIC · KYMRIAH · Kyprolis · Neulasta · POTELIGEO · Perjeta · REZUROCK · RYDAPT · Revlimid · SOLIRIS · TECENTRIQ · Tavalisse · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · XGEVA · XTANDI · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (76%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $23 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
104
Per 100K population
10.3
County median income
$68,447
Nearest hospital
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Iqbal is a mixed practice specialist, with above-average Medicare volume (top 14% in FL), with consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Iqbal experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Iqbal performed 8,000 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iqbal receive payments from pharmaceutical companies?
Yes. Dr. Iqbal received a total of $12,910 from 21 companies across 61 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iqbal's costs compare to other hematology & oncology specialists in Jacksonville?
Dr. Iqbal's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iqbal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Jacksonville
Browse hematology & oncology specialists in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology